Investment
Features
FeesSafety
Academy
More
Pluang+

Compare nVent Electric (NVT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

nVent ElectricTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

nVent Electric vs Regeneron Pharmaceuticals Inc — how do they compare? nVent Electric trades at $158.56 (market cap $26.31B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.2× nVent Electric's market cap, and nVent Electric pays the higher dividend (0.52%). Which is the better fit depends on your goals.

NVTREGN
Market Cap
$26.31B$83.43B
Sector
IndustrialsHealth
52-Week High
$184.34$852.03
52-Week Low
$94.78$555.51
Enterprise Value
$27.69B$78.14B
Dividend Yield
0.52%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

nVent Electric

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About nVent Electric

nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.

Read more on NVT

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN